Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thymosin alpha 1: from bench to bedside.

Enrico Garaci1, Cartesio Favalli, Francesca Pica

  • 1University of Rome Tor Vergata, Rome, Italy.

Annals of the New York Academy of Sciences
|June 30, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal humoral and memory B-cell responses to repeated SARS-CoV-2 vaccination in long-term care facilities residents.

Immunity & ageing : I & A·2026
Same author

Facing Antimicrobial Resistance and Virulence in Streptococcus agalactiae During Late Pregnancy: Evaluation of Lactobacilli as a Supportive Approach.

MicrobiologyOpen·2026
Same author

Efficacy of hyaluronic acid and butyroyl glutathione in the management of glaucoma-related ocular surface disease: a prospective, interventional, double-blind, cross-over post market study.

Frontiers in pharmacology·2026
Same author

Serum cytokine profiling reveals CXCL10 (IP-10) as a major predictor of severe COVID-19 outcomes in hospitalized patients during the first pandemic wave in Italy.

Frontiers in immunology·2026
Same author

Scenario analysis for potential community spread of Andes virus (ANDV).

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

First case of penicillin-resistant <i>Streptococcus agalactiae</i> (group B <i>Streptococcus</i>) isolated from an adult patient in Italy, February 2026.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

Thymosin alpha 1 (Talpha1) combined with interferon (IFN) and chemotherapy shows efficacy in preclinical cancer models and early human trials for melanoma and non-small cell lung cancer. This combination therapy also demonstrates potential in treating chronic hepatitis B and C.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Thymosin alpha 1 (Talpha1) and interferon (IFN) combination therapy has shown initial promise in preclinical cancer models.
  • Preclinical studies in Lewis lung carcinoma, Friend erythroleukemia, B16 melanoma, and DHD/K12 colorectal cancer models confirmed efficacy.
  • These findings supported the initiation of clinical trials for Talpha1 in combination with biological response modifiers (BRMs) and/or chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy of Talpha1 in combination with BRMs and/or chemotherapy in preclinical and clinical settings.
  • To investigate the potential of Talpha1 and IFN-alpha in treating advanced non-small cell lung cancer (NSCLC) and melanoma.
  • To explore the use of Talpha1 in combination therapy for chronic hepatitis B and C infections.

Main Methods:

Related Experiment Videos

  • Combination therapy involving Talpha1 with IFN, IL-2, and chemotherapy (cyclophosphamide, cis-platinum, dacarbazine) was tested in various animal models.
  • Clinical trials were conducted involving patients with advanced NSCLC, melanoma, and chronic hepatitis B and C.
  • Mechanism of action studies investigated Talpha1's role in activating dendritic cells and influencing antigen expression.

Main Results:

  • Pivotal trials demonstrated the potential of Talpha1 and low-dose IFN-alpha in treating human cancers like NSCLC and melanoma.
  • The combination therapy was effective in patients with chronic hepatitis B and C, including non-responders and those with specific viral genotypes.
  • Talpha1 was shown to activate dendritic cells via Toll-like receptor signaling and increase tumor, viral, and MHC I antigen expression.

Conclusions:

  • Combination therapy with Talpha1, IFN, and chemotherapy holds significant potential for treating various cancers.
  • Talpha1 exhibits immunomodulatory effects, enhancing the immune response against tumors and viral infections.
  • Ongoing clinical trials are further investigating Talpha1's efficacy and optimal dosing in melanoma and hepatitis C treatment.